Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Innate Pharma S.A. ADR (IPHA)
Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 217,290
  • Shares Outstanding, K 80,861
  • Annual Sales, $ 60,770 K
  • Annual Income, $ -61,220 K
  • 60-Month Beta 0.29
  • Price/Sales 4.46
  • Price/Cash Flow 7.12
  • Price/Book 3.39
Trade IPHA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.32 +13.79%
on 02/02/24
2.89 -8.56%
on 01/30/24
-0.06 (-2.22%)
since 01/26/24
3-Month
2.27 +16.43%
on 12/07/23
3.07 -13.95%
on 01/04/24
+0.21 (+8.64%)
since 11/28/23
52-Week
1.81 +45.86%
on 11/01/23
3.57 -26.05%
on 06/12/23
-0.31 (-10.51%)
since 02/28/23

Most Recent Stories

More News
Why Shares of Innate Pharma Jumped Thursday

The company's collaboration agreement with Sanofi could soon pay off.

SNY : 48.00 (-0.44%)
TAK : 14.65 (-1.28%)
IPHA : 2.64 (-1.76%)
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today three abstracts including Innate’s product candidates have been accepted for the American...

IPHA : 2.64 (-1.76%)
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8...

IPHA : 2.64 (-1.76%)
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”)...

IPHA : 2.64 (-1.76%)
Innate Pharma to Participate in Upcoming Investor Conference

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...

IPHA : 2.64 (-1.76%)
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation,...

IPHA : 2.64 (-1.76%)
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 12, 2023 in its...

IPHA : 2.64 (-1.76%)
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2022 Universal Registration Document ( Document d’enregistrement universel...

IPHA : 2.64 (-1.76%)
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research...

IPHA : 2.64 (-1.76%)
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its consolidated financial results 1 for the year ending December 31, 2022. The consolidated...

IPHA : 2.64 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.

See More

Key Turning Points

3rd Resistance Point 2.75
2nd Resistance Point 2.69
1st Resistance Point 2.67
Last Price 2.64
1st Support Level 2.59
2nd Support Level 2.53
3rd Support Level 2.51

See More

52-Week High 3.57
Fibonacci 61.8% 2.90
Fibonacci 50% 2.69
Last Price 2.64
Fibonacci 38.2% 2.48
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar